How Colorectal Tumors Escape KRAS Inhibitors Identified
Researchers have uncovered how KRAS-mutant colorectal cancers evade KRAS inhibitors through both genetic mutations and adaptive inflammatory signaling, with TBK...
Researchers have uncovered how KRAS-mutant colorectal cancers evade KRAS inhibitors through both genetic mutations and adaptive inflammatory signaling, with TBK1 emerging as a promising target to improve treatment durability. The post How Colorectal Tumors Escape KRAS Inhibitors Identified appeared first on Inside Precision Medicine .